.jpg)
Susan is a member of the investment team, where she focuses on therapeutics, tools, bio-infrastructures and broader applications of biology.
Prior to 8VC, Susan was a part of the Biotech investing team at Insight Partners. Before that, she was a Venture Investing Fellow at 5AM Ventures, focusing on therapeutics investing and venture creation. She did research at the Broad Institute in the Lander Lab, where she worked on stem cell reprogramming and differentiation.
Susan graduated from Wellesley College and completed her PhD at Duke University in Computational Biology and Bioinformatics. She was a member of the Gersbach Lab at Duke, developing software and statistical modeling for scCRISPR screens. She grew up in China and Australia.
What’s a Rich Text element?
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
Static and dynamic content editing
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
How to customize formatting for each rich text
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
The Two-Antibody Problem: Announcing the BigHat-Anthropic Partnership
Today, Anthropic and BigHat Biosciences announced a historic collaboration: a single Anthropic researcher, armed with Claude, operated BigHat’s automated lab to optimize two antibodies. This marks one of the first instances of a frontier AI lab and next-gen bio lab teaming up, and a potential watershed for drug discovery.
The Two-Antibody Problem: Announcing the BigHat-Anthropic Partnership
Today, Anthropic and BigHat Biosciences announced a historic collaboration: a single Anthropic researcher, armed with Claude, operated BigHat’s automated lab to optimize two antibodies. This marks one of the first instances of a frontier AI lab and next-gen bio lab teaming up, and a potential watershed for drug discovery.
Orchestra Bio is Joining OpenAI
Today, Orchestra announced they will join OpenAI to build their life sciences applications.
Orchestra Bio is Joining OpenAI
Today, Orchestra announced they will join OpenAI to build their life sciences applications.
The Crisis and Opportunity in Rare Diseases
8VC stepped into life sciences to bridge the gap between groundbreaking biomedical innovation and real-world patient care. Our collaborations with visionary scientists have already begun transforming deadly diseases into manageable conditions, and in some cases, outright cures. Despite the immense potential of advanced diagnostics and therapies, however, rare disease medicine remains starkly underdeveloped. At their core, the unmet needs in rare diseases are not only scientific or medical challenges, but fundamental misalignments of commercial and societal incentives.
The Crisis and Opportunity in Rare Diseases
8VC stepped into life sciences to bridge the gap between groundbreaking biomedical innovation and real-world patient care. Our collaborations with visionary scientists have already begun transforming deadly diseases into manageable conditions, and in some cases, outright cures. Despite the immense potential of advanced diagnostics and therapies, however, rare disease medicine remains starkly underdeveloped. At their core, the unmet needs in rare diseases are not only scientific or medical challenges, but fundamental misalignments of commercial and societal incentives.
